版本:
中国

BRIEF-Auris Medical reports key results from Keyzilen Ampact2 open-label extension study

April 24 Auris Medical Holding Ag

* Auris medical reports key results from Keyzilen Ampact2 open-label extension study

* Trial outcomes show positive safety profile of Keyzilen for chronic intermittent use

* Exploratory efficacy results support therapeutic concept of early tinnitus treatment

* Says trial outcomes show positive safety profile of Keyzilen for chronic intermittent use

* Says auris medical expects to announce results from ampact1, open-label extension study related to TACTT2, later this quarter

* TACTT3 extended to recruit additional 60 patients in each of stratum A and B, enrollment ongoing; top-line results expected in early 2018

* As recruitment for Ampact2 has completed, open-label extension is not offered to patients currently enrolling in extended TACTT3 trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐